(Q38185936)

30 August 2017

title

Potential of new therapies like anti-PD1 in kidney cancer (English)

1 reference

30 August 2017

Anasuya Gunturi

1

1 reference

30 August 2017

David F McDermott

series ordinal

2

1 reference

30 August 2017

publication date

1 March 2014

1 reference

Current Treatment Options in Oncology

30 August 2017

published in

1 reference

30 August 2017

volume

15

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

137-146

1 reference

PD-1 and its ligands in T-cell immunity

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0268-Y

Clinical implications of circulating angiogenic factors in cancer patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24504486

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24504486

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24504486

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11864-013-0268-Y

1 reference

Dimensions Publication ID

30 August 2017

1044252407

0 references

1 reference